You are viewing the site in preview mode
Skip to main content
|
Histopathologic diagnosis
|
Management
|
Row total
|
|---|
|
No treatment indicated (row%) (column%)
|
Immediate management based on colposcopic impression (row%) (column%)
|
Delayed excisional treatment on a recall visit (row%) (column%)
|
|---|
|
With ablation
|
With LLETZ
|
Completed
|
Pendinga
|
|---|
|
<CIN2
|
1158 (88.7%) (100.0%)
|
90 (6.9%) (78.9%)
|
54 (4.1%) (69.2%)
|
3c (0.2%) (12.0%)
|
0
|
1305 (100%)
|
|
CIN2
|
Diagnosed on biopsy/LLETZ
|
0
|
10 (40.0%) (8.8%)
|
11 (44.0%) (14.1%)
|
2 (8.0%) (8.0%)
|
2 (8.0%) (16.7%)
|
25 (100%)
|
|
Diagnosed on ECC
|
0
|
0
|
0
|
8 (66.7%) (32.0%)
|
4 (33.3%) (33.3%)
|
12 (100%)
|
|
CIN3
|
Diagnosed on biopsy/LLETZ
|
0
|
13 (38.2%) (11.4%)
|
12 (35.3%) (15.4%)
|
5 (14.7%) (20.0%)
|
4 (11.8%) (33.3%)
|
34 (100%)
|
|
Diagnosed on ECCb
|
0
|
1 (16.7%) (0.9%)
|
0
|
3 (50.0%) (12.0%)
|
2 (33.3%) (16.7%)
|
6 (100%)
|
|
Cancer
|
Diagnosed on biopsy/LLETZ
|
0
|
0
|
1d (20.0%) (1.3%)
|
4 (80.0%) (16.0%)
|
0
|
5 (100%)
|
|
Column total
|
1158 (100%)
|
114 (100%)
|
78 (100%)
|
25 (100%)
|
12 (100%)
|
Grand total = 1387
|
- aRecall attempts are temporarily paused due to COVID-19 pandemic spread
- bIncludes two women with OncoE6 HPV 16 positive, in whom LLETZ was recommended on recall and is still incomplete
- cIncludes one case with colposcopic impression of cancer treated with hysterectomy of what eventually turned out to be <CIN2; other two cases were recalled for LLETZ due to reporting error
- dInvasive squamous cell carcinoma with CIN3 at margins was diagnosed on on-site LLETZ leading to a recall for a repeat LLETZ with CIN3 diagnosis leading to a 2nd recall for a hysterectomy
